Positive News SentimentPositive NewsNASDAQ:PRCT PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free PRCT Stock Alerts $49.42 +0.58 (+1.19%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$48.89▼$50.4250-Day Range$45.34▼$50.7552-Week Range$24.83▼$52.32Volume555,747 shsAverage Volume494,350 shsMarket Capitalization$2.52 billionP/E RatioN/ADividend YieldN/APrice Target$45.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get PROCEPT BioRobotics alerts: Email Address PROCEPT BioRobotics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside7.7% Downside$45.60 Price TargetShort InterestHealthy8.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.62Based on 3 Articles This WeekInsider TradingSelling Shares$6.15 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.00) to ($1.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.13 out of 5 starsMedical Sector862nd out of 938 stocksSurgical & Medical Instruments Industry86th out of 94 stocks 1.5 Analyst's Opinion Consensus RatingPROCEPT BioRobotics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $45.60, PROCEPT BioRobotics has a forecasted downside of 7.7% from its current price of $49.42.Amount of Analyst CoveragePROCEPT BioRobotics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.52% of the float of PROCEPT BioRobotics has been sold short.Short Interest Ratio / Days to CoverPROCEPT BioRobotics has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in PROCEPT BioRobotics has recently decreased by 8.85%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPROCEPT BioRobotics does not currently pay a dividend.Dividend GrowthPROCEPT BioRobotics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRCT. Previous Next 3.1 News and Social Media Coverage News SentimentPROCEPT BioRobotics has a news sentiment score of 1.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for PROCEPT BioRobotics this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added PROCEPT BioRobotics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PROCEPT BioRobotics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,153,402.00 in company stock.Percentage Held by Insiders19.60% of the stock of PROCEPT BioRobotics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.46% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($2.00) to ($1.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PROCEPT BioRobotics is -22.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PROCEPT BioRobotics is -22.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPROCEPT BioRobotics has a P/B Ratio of 8.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here About PROCEPT BioRobotics Stock (NASDAQ:PRCT)PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.Read More PRCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRCT Stock News HeadlinesMarch 21, 2024 | insidertrades.comInsider Selling: PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Sells 441 Shares of StockMarch 21, 2024 | insidertrades.comInsider Selling: PROCEPT BioRobotics Co. (NASDAQ:PRCT) CFO Sells 1,024 Shares of StockMarch 29, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. March 17, 2024 | insidertrades.comAlaleh Nouri Sells 2,749 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) StockMarch 22, 2024 | americanbankingnews.comReza Zadno Sells 5,391 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) StockMarch 20, 2024 | finance.yahoo.comPROCEPT BioRobotics Corp (PRCT) President and CEO Reza Zadno Sells Company SharesMarch 18, 2024 | finance.yahoo.comPRCT Oct 2024 55.000 callMarch 16, 2024 | ca.finance.yahoo.comPRCT Apr 2024 50.000 putMarch 29, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. March 8, 2024 | finance.yahoo.comEVP, CLO, Corporate Secretary Alaleh Nouri Sells Shares of PROCEPT BioRobotics Corp (PRCT)March 7, 2024 | finance.yahoo.comDirector Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)March 1, 2024 | nasdaq.comNoteworthy Wednesday Option Activity: ZM, PRCT, MSTRMarch 1, 2024 | finance.yahoo.comPROCEPT BioRobotics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsFebruary 29, 2024 | ca.finance.yahoo.comPRCT Jul 2024 70.000 callFebruary 29, 2024 | ca.finance.yahoo.comPRCT Mar 2024 70.000 callFebruary 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Pliant Therapeutics (PLRX) and Viridian Therapeutics (VRDN)February 28, 2024 | markets.businessinsider.comTruist Securities Maintains Buy Rating for PROCEPT BioRobotics: Here's What You Need To KnowFebruary 28, 2024 | finance.yahoo.comPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comQ4 2023 Procept Biorobotics Corp Earnings CallFebruary 28, 2024 | investors.comBio Stock Procept BioRobotics Eyes Rare Buy Trigger After EarningsFebruary 27, 2024 | seekingalpha.comPROCEPT BioRobotics Corporation 2023 Q4 - Results - Earnings Call PresentationFebruary 27, 2024 | benzinga.comPROCEPT BioRobotics: Q4 Earnings InsightsFebruary 27, 2024 | globenewswire.comPROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 ResultsFebruary 26, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on PROCEPT BioRobotics (PRCT)February 26, 2024 | benzinga.comPROCEPT BioRobotics's Earnings: A PreviewFebruary 24, 2024 | thestreet.comPROCEPT BioRobotics CorporationFebruary 20, 2024 | finance.yahoo.comPROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Should You Buy?See More Headlines Receive PRCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/29/2024Next Earnings (Estimated)4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PRCT CUSIPN/A CIK1588978 Webwww.procept-biorobotics.com Phone650-232-7200FaxN/AEmployees626Year FoundedN/APrice Target and Rating Average Stock Price Target$45.60 High Stock Price Target$58.00 Low Stock Price Target$37.00 Potential Upside/Downside-7.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-105,900,000.00 Net Margins-77.75% Pretax Margin-77.76% Return on Equity-46.59% Return on Assets-30.63% Debt Debt-to-Equity Ratio0.18 Current Ratio7.63 Quick Ratio6.77 Sales & Book Value Annual Sales$136.19 million Price / Sales18.49 Cash FlowN/A Price / Cash FlowN/A Book Value$5.56 per share Price / Book8.89Miscellaneous Outstanding Shares50,960,000Free Float40,975,000Market Cap$2.52 billion OptionableOptionable Beta1.02 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Reza Zadno Ph.D. (Age 69)President, CEO & Director Comp: $1.26MMr. Kevin Waters (Age 47)Executive VP & CFO Comp: $744.1kMs. Alaleh Nouri (Age 45)EVP, Chief Legal Officer & Corporate Secretary Comp: $713.61kMr. Hisham Shiblaq (Age 48)Executive VP & Chief Commercial Officer Comp: $757.2kMr. Mohan F. Sancheti (Age 60)Senior Vice President of Operations Mr. Barry TemplinExecutive VP of Technology & Clinical DevelopmentMr. Matthew James Bacso C.F.A.Vice President of Investor RelationsMs. Stacey L. Porter (Age 48)Chief People Officer Mr. Bijesh ChandranSenior Vice President of Regulatory Affairs & Quality AssuranceMore ExecutivesKey CompetitorsICU MedicalNASDAQ:ICUITandem Diabetes CareNASDAQ:TNDMIntegra LifeSciencesNASDAQ:IARTInari MedicalNASDAQ:NARIAlphatecNASDAQ:ATECView All CompetitorsInsiders & InstitutionsFairman Group LLCBought 2,000 shares on 3/26/2024Ownership: 0.004%Reza ZadnoSold 5,391 sharesTotal: $263,242.53 ($48.83/share)Kevin WatersSold 1,024 sharesTotal: $50,001.92 ($48.83/share)Alaleh NouriSold 441 sharesTotal: $21,534.03 ($48.83/share)Vanguard Group Inc.Bought 109,694 shares on 3/11/2024Ownership: 8.212%View All Insider TransactionsView All Institutional Transactions PRCT Stock Analysis - Frequently Asked Questions Should I buy or sell PROCEPT BioRobotics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PROCEPT BioRobotics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRCT shares. View PRCT analyst ratings or view top-rated stocks. What is PROCEPT BioRobotics' stock price target for 2024? 6 analysts have issued 1-year target prices for PROCEPT BioRobotics' shares. Their PRCT share price targets range from $37.00 to $58.00. On average, they expect the company's share price to reach $45.60 in the next year. This suggests that the stock has a possible downside of 7.7%. View analysts price targets for PRCT or view top-rated stocks among Wall Street analysts. How have PRCT shares performed in 2024? PROCEPT BioRobotics' stock was trading at $41.91 on January 1st, 2024. Since then, PRCT shares have increased by 17.9% and is now trading at $49.42. View the best growth stocks for 2024 here. When is PROCEPT BioRobotics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our PRCT earnings forecast. How were PROCEPT BioRobotics' earnings last quarter? PROCEPT BioRobotics Co. (NASDAQ:PRCT) announced its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.10. The company had revenue of $43.58 million for the quarter, compared to analyst estimates of $41.79 million. PROCEPT BioRobotics had a negative net margin of 77.75% and a negative trailing twelve-month return on equity of 46.59%. The firm's revenue was up 83.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.56) earnings per share. What ETFs hold PROCEPT BioRobotics' stock? ETFs with the largest weight of PROCEPT BioRobotics (NASDAQ:PRCT) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), ALPS Disruptive Technologies ETF (DTEC) and Global X Robotics & Artificial Intelligence Thematic ETF (BOTZ).iShares U.S. Medical Devices ETF (IHI). What guidance has PROCEPT BioRobotics issued on next quarter's earnings? PROCEPT BioRobotics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $210.0 million-$210.0 million, compared to the consensus revenue estimate of $204.5 million. When did PROCEPT BioRobotics IPO? PROCEPT BioRobotics (PRCT) raised $126 million in an IPO on Wednesday, September 15th 2021. The company issued 5,500,000 shares at $22.00-$24.00 per share. Who are PROCEPT BioRobotics' major shareholders? PROCEPT BioRobotics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.29%), Vanguard Group Inc. (8.21%), Price T Rowe Associates Inc. MD (2.98%), Price T Rowe Associates Inc. MD (2.98%), Wellington Management Group LLP (2.09%) and Bellevue Group AG (1.75%). Insiders that own company stock include Alaleh Nouri, Frederic H Moll, Global Investors Lp Viking, Hisham Shiblaq, Kevin Waters, Morgan Colby Wood, Reza Zadno and Thomas M Krummel. View institutional ownership trends. How do I buy shares of PROCEPT BioRobotics? Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRCT) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PROCEPT BioRobotics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.